GLOW is a 70 mg single-vial peptide blend injected under the skin to rebuild collagen, firmness, and texture — the structural layer topical skincare cannot reach. It carries three peptides: GHK-Cu, BPC-157, and full-length TB-4. GHK-Cu does the collagen work, BPC-157 supplies the blood flow that feeds it, and TB-4 keeps the new tissue organized.
No FDA-approved GLOW blend exists, and no trial has tested the three peptides together. The evidence is per-compound: decades of dermatology and gene-expression work behind GHK-Cu, a large preclinical base plus early human trials for BPC-157, and wound-healing data for TB-4. The practical risks are vial identity, sterility, and the reconstitution math — not the biology.
GLOW is built for calm skin: aging, fine lines, firmness loss, scar improvement, hair-growth support. When inflammation is interfering — rosacea, post-procedure redness, reactive flushing — KLOW adds a fourth peptide for that, and switching is a vial swap.
| At a Glance | |
|---|---|
| What it is | 70 mg three-peptide blend (GHK-Cu, BPC-157, TB-4) for subcutaneous skin repair |
| GLOW dosage | 2 mg GHK-Cu anchor per dose, plus 400 mcg each of BPC-157 and TB-4. Reconstitution math on the calculator. |
| Protocol | Daily weeks 1-4, 5x weekly weeks 5-8, then 2-3x weekly maintenance |
| Best for | Firmness, fine lines, texture, scar remodeling, hair-growth support on calm skin |
| Results timeline | Texture by 2-4 weeks; fine lines by 4-8; firmer structure and scar remodeling by 8-12 |
| Side effects | Mild injection-site reactions; a 30-60 second GHK-Cu sting; the solution is naturally blue |
| Regulatory status | No FDA-approved GLOW blend. The real concerns are vial identity, sterility, and dose math. |
What Is in GLOW
GLOW is 70 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-4 10 mg. GHK-Cu carries most of the mass — about 71% — because collagen synthesis is the continuous daily demand. BPC-157 and TB-4 work at lower doses because their effective concentrations are lower, not because they matter less.
| Component | Amount | Role |
|---|---|---|
| GHK-Cu | 50 mg | Collagen synthesis, gene regulation, antioxidant defense |
| BPC-157 | 10 mg | Capillary network, tissue-barrier stabilization |
| TB-4 | 10 mg | Cell migration, tissue organization, anti-scarring signaling |
"GLOW blend" and "GLOW stack" both name this same three-peptide single-vial composition; some peptide vocabularies use "stack" for multi-vial protocols, but for GLOW the two terms point to the same vial. The 50/10/10 split is built for cosmetic use — continuous collagen-gene activation, with the smaller peptides as precision support.
How GLOW Works
Skin aging is several systems slowing at once: collagen genes firing less, the capillary supply thinning, and repair cells losing coordination. GLOW assigns one peptide to each. Run any one alone and the part the missing peptide handles becomes the rate-limiter for the whole protocol.
GHK-Cu: collagen and structure
GHK-Cu is a copper-binding tripeptide mapped across more than 4,000 genes: collagen synthesis, antioxidant defense, and wound-healing programs trend up; inflammation and tissue-breakdown programs trend down¹. Circulating levels fall with age, from roughly 200 ng/mL at 20 to about 80 ng/mL by 60. It both clears damaged matrix and lays down replacement collagen, where most collagen interventions only do the second — which is why old scars and sun damage remodel rather than just sitting under fresh collagen. The copper it carries is also why the solution is blue and why a fresh dose stings briefly.
BPC-157: blood supply
BPC-157 is a 15-amino-acid fragment from gastric juice. It builds the capillary network active regeneration depends on (new blood vessel formation²) and stabilizes tissue barriers so new tissue holds together instead of breaking down. Without blood flow to the dermis, GHK-Cu has the signal but the raw material never reaches the work. Skin color and tone improve as the microvascular network fills in.
TB-4: cell migration
Full-length thymosin beta-4 (43 amino acids) governs how repair cells move into and organize inside tissue³. It biases healing toward functional tissue rather than rope-like scarring and calms blood-vessel cells, which shows up as less redness and swelling. GLOW uses the full-length parent, not the shorter TB-500 fragment sold for injury repair. The two get blurred on labels routinely⁵, so check what sequence is actually in the vial.
GLOW Dosage
Each GLOW dose anchors on 2 mg GHK-Cu and delivers 400 mcg each of BPC-157 and TB-4. The schedule changes the frequency across three phases, never the per-dose amount.
GLOW dosage chart
| Compound | Per dose | Phase 1 (wks 1-4) | Phase 2 (wks 5-8) | Phase 3 (wks 9+) |
|---|---|---|---|---|
| GHK-Cu | 2 mg | Daily | 5x/week | 2-3x weekly |
| BPC-157 | 400 mcg | Daily | 5x/week | 2-3x weekly |
| TB-4 | 400 mcg | Daily | 5x/week | 2-3x weekly |
The reconstitution math — bacteriostatic water volume, the syringe draw for your vial size, and any custom anchor — lives on the GLOW Dosage Calculator. General syringe handling is in the Reconstitution Guide.
GLOW Protocol: Three-Phase Schedule
The mixture never changes across the protocol — only the frequency does. The per-injection dose holds at 2 mg GHK-Cu through every phase.
Phase 1: activation (weeks 1-4)
Daily dosing. GHK-Cu switches on collagen production and supplies the copper for proper cross-linking. BPC-157 builds the small-vessel supply that feeds active tissue. TB-4 mobilizes and organizes repair cells. Expect hydration to improve, tone to even out, and texture to soften.
Phase 2: remodeling (weeks 5-8)
Five times weekly, same per-dose amount. All three peptides run at peak coordinated activity. GHK-Cu drives maximum collagen and elastin output; small dermatology studies report meaningful gains in collagen synthesis and reductions in wrinkle depth over 8-12 weeks¹. Fine lines soften, elasticity improves, skin thickness increases.
Phase 3: maintenance (weeks 9+)
Two or three times weekly. Newly synthesized collagen needs 48-72 hours between pulses to organize and cross-link, so a pulsed cadence holds results without the constant pressure of daily dosing. Run it ongoing, or return to a 4-week daily intensive every three to four months.
A standard cycle is 12 weeks active, then a step down to maintenance or 4-8 weeks off. Indefinite daily dosing is not the default — no long-term human data exists for the blend, so a cadence is the conservative choice.
Timeline: What to Expect
| Week | What is happening | What you notice |
|---|---|---|
| 2 | Collagen gene activation, vascular network forming | Hydration up, smoother texture |
| 4-6 | Peak collagen synthesis, organized migration | Fine lines soften, tone evens, elasticity returns |
| 8-10 | Matrix remodeling and integration | Pore refinement, visible glow, skin density up |
| 12+ | Sustained collagen quality | Stable firmness, older scars start remodeling |
Architectural change runs ahead of mirror-visible change for the first month, so baseline week-0 photos are the cleanest way to track it.
Where to Inject GLOW
Inject subcutaneously, rotating sites to prevent irritation. For the skincare anchor, the site does not need to be near the face — GHK-Cu works at nanomolar concentrations within systemic-delivery range, and injection at one site supports skin quality broadly⁴.
- Abdomen — the default; easy pinch, generous subcutaneous tissue, simple rotation across four quadrants.
- Thigh — the front or outer thigh works well and keeps the abdomen free for rotation.
- Lateral hip — a comfortable third site for longer protocols.
Keep at least 2 cm between injection points within a session, and alternate zones across the week (left abdomen, right abdomen, left thigh, right thigh) on long-running protocols. The broader anatomical map for individual compounds is in the where-to-inject guide.
Supporting Factors
| Component | Target | Why |
|---|---|---|
| Protein | At least 1.6 g/kg daily | Raw material for tissue synthesis |
| Vitamin C | 500-1,000 mg daily | Collagen cross-linking cofactor |
| Hydration | 2-3 L daily | Matrix hydration |
| Zinc | 15-25 mg if supplementing copper | Copper-zinc balance |
| Sleep | 7-9 hours | Collagen synthesis peaks in deep sleep |
Optional adjuncts: red-light therapy (630-670 nm) for 10-20 minutes daily, and microneedling every three to four weeks during Phase 2.
Safety and Contraindications
Do not use GLOW with active malignancy or a cancer history under five years (GHK-Cu, BPC-157, and TB-4 promote new blood vessel formation), with Wilson's disease or copper-metabolism disorders (GHK-Cu), during pregnancy or breastfeeding, within two weeks of major surgery, or with a known allergy to any component.
Side effects are uncommon and usually mild: injection-site redness or slight swelling, the GHK-Cu sting, transient warmth or flushing, occasional mild fatigue. If skin turns reactive on GLOW — new redness or flushing that was not there before — that is inflammatory tone interfering with the collagen signal, and KLOW is the switch, not a higher GLOW dose. Persistent hives, swelling, throat tightness, or breathing changes are not a normal peptide flush; stop and seek care.
No long-term human data exists for GLOW as a blend, so indefinite daily use is not the default. The hard contraindications above apply at any duration.
What Evidence Exists
| Compound | Evidence base |
|---|---|
| GHK-Cu | Split-face human dermatology trials on wrinkle depth and skin density (n usually under 50 per arm); microarray gene mapping (4,000+ genes); decades of cosmetic and wound-healing literature. No multi-center RCT. |
| BPC-157 | 100+ preclinical studies in injury, GI, and tendon models; small early human trials (2024-2025) on tendon and gut. No published Phase 3. |
| TB-4 | Preclinical wound-healing data (dermal, cardiac, neural); Phase 2/3 ophthalmic trials in corneal healing; cosmetic dosing extrapolated from injury models. |
No controlled trial has evaluated GLOW as a blend. Synergy is inferred from the individual mechanisms, not demonstrated in combination.
FAQ
What is GLOW peptide?
GLOW is a 70 mg three-peptide blend (GHK-Cu, BPC-157, and full-length TB-4) injected under the skin to rebuild collagen, firmness, and texture. It works on the structural layer beneath what topicals reach. GHK-Cu drives collagen, BPC-157 supplies the blood flow that feeds it, and TB-4 keeps the new tissue organized.
What are the benefits of GLOW?
GLOW works below where topicals reach, on the structural layer where firmness lives. GHK-Cu activates collagen genes and supplies the copper cofactor for cross-linking; BPC-157 builds the capillary network that feeds active tissue; full-length TB-4 organizes repair cells with an anti-scarring bias. Practical readouts: hydration and texture by 2-4 weeks, fine lines softening by 4-8, firmer structure and scar remodeling by 8-12.
What is the difference between GLOW and KLOW?
KLOW is GLOW plus a fourth peptide, KPV, an anti-inflammatory tripeptide that pre-empts the inflammation switch (NF-kB). The shared three are identical at the same masses. Use GLOW when skin is calm and the goal is firmness, fine lines, or texture; use KLOW when inflammation is part of the picture: rosacea, post-procedure, reactive flushing. Same dosing math, so switching mid-cycle is a vial swap.
What are the side effects of GLOW?
The most common is a 30-60 second sting from GHK-Cu's copper content, which fades quickly and does not signal contamination. Others are mild and uncommon: injection-site redness or swelling, transient warmth or flushing, occasional mild fatigue. If skin turns newly reactive, switch to KLOW rather than raising the GLOW dose. Persistent hives, swelling, throat tightness, or breathing changes are not a normal flush — stop and seek care.
How long does a GLOW cycle run?
Twelve weeks active is standard: daily for weeks 1-4, five times weekly for weeks 5-8, then 2-3 times weekly through week 12. After that, step down to maintenance or take 4-8 weeks off. Pulsed maintenance holds results without blunting the response, so indefinite daily dosing is not the default. Some users run a 4-week daily intensive every three to four months instead.
What results should you expect, and when?
Architectural change runs ahead of visible change for the first month. Roughly: hydration up and texture softer by weeks 2-4; fine lines visibly softer and tone more even by 4-6; pore refinement and a visible glow by 8-10; sustained firmness and scar remodeling by 12+. Individual response varies and progress is gradual, so week-0 baseline photos are the cleanest way to see it.
Can you make GLOW from separate vials?
Yes. Buy GHK-Cu, BPC-157, and full-length TB-4 individually, then reconstitute together or run separate injections. Individual vials are usually cheaper per mg but mean three cold-chain items, more sterile draws per dose, and matching the 50/10/10 ratio yourself. A pre-mixed vial trades cost for fewer mistakes.
Can you use GLOW with GLP-1 medications?
Yes. The mechanisms do not overlap, and pairing is common during weight-loss phases. Rapid GLP-1-driven loss often outpaces the skin's ability to remodel, and GLOW supports collagen directly through the loss curve. If you are in a caloric deficit, consider adding NAD+ as a metabolic floor.
At what age should you start GLOW?
Mid-30s to early 40s is the typical recommendation, when collagen production declines about 1% per year after 30. Earlier use can make sense with substantial sun damage or scarring. Below the mid-20s the substrate is not depleted enough for the effect to register clearly.
Related Topics
- KLOW Peptide Protocol — adds KPV for reactive or inflamed skin
- GHK-Cu for Skin — GHK-Cu mechanism deep-dive
- GLOW Dosage Calculator — solve any anchor dose, vial size, or draw volume
- BPC-157 Guide — BPC-157 standalone use
- Where to Inject Peptides — injection map for GLOW and individual compounds
- Reconstitution Guide — technique for all peptide vials
- TB-500 Guide — the injury-oriented fragment, distinct from the TB-4 in GLOW
References
¹ GHK-Cu gene modulation — COL1A1/COL3A1 collagen activation, lysyl-oxidase cross-linking, bidirectional MMP regulation, SOD/catalase antioxidant expression, 4,000+ gene modulation via microarray; age-related plasma decline: Pickart L, Margolina A. Int J Mol Sci 2018. DOI: 10.3390/ijms19071987
² BPC-157 angiogenic signaling — VEGF expression, tight-junction upregulation, capillary sprouting, microvascular network formation; rodent and dog IV PK characterization: Sikiric P et al. Curr Pharm Des 2018. PMC8275860; He L et al. Front Pharmacol 2022. PMC9794587
³ Thymosin beta-4 tissue repair — G-actin sequestration for cell mobility, TGF-beta anti-scarring regulation, M2 macrophage polarization, endothelial anti-inflammatory effects: Goldstein AL et al. Trends Mol Med 2005. PubMed 16099219
⁴ GHK-Cu systemic delivery — effective at nanomolar concentrations; thigh-muscle injection produced healing at distant wound sites across rats, mice, and pigs: Cushman CJ et al. Yale J Biol Med 2024;97(3):399-413. PMC11426299
⁵ TB-4 / TB-500 product mislabeling — documented bidirectional mislabeling between full-length TB-4 (43 aa, ~4,900 Da) and the TB-500 fragment (17-23, ~800 Da): Esposito M et al. Drug Test Anal 2012. PubMed 22962027